For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
For laboratory research use only. Not for human consumption. Not for clinical or therapeutic use. Not evaluated by the FDA.
Research Comparison
CJC-1295 and Tesamorelin are both GHRH analogs that act on the GHRH receptor, but they differ in modification and duration. CJC-1295 with DAC is engineered for a long, sustained half-life, while Tesamorelin uses a trans-3-hexenoic acid modification for stability.
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Modification | Drug Affinity Complex (DAC) | Trans-3-hexenoic acid |
| Half-life profile | Extended (days) | Stabilized (hours) |
| Research focus | Sustained GH-axis signaling | GHRH-receptor and GH-axis signaling |
Both are GHRH analogs acting on the GHRH receptor, but they use different chemical modifications. CJC-1295 (DAC) is engineered for an extended half-life; Tesamorelin is stabilized for GH-axis and metabolic research.